Disease progression and survival in HIV-1-infected Afri

Aids

12, 1203-1209

DOI: 10.1097/00002030-199810000-00013

Citation Report

#	Article	IF	Citations
1	Immunologic And Clinical Stages in HIV-1–Infected Ugandan Adults Are Comparable and Provide No Evidence of Rapid Progression but Poor Survival With Advanced Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 509.	0.9	44
2	Changes in AIDS-Defining Illnesses in a London Clinic, 1987–1998. Journal of Acquired Immune Deficiency Syndromes, 1999, 21, 401.	0.3	18
3	Survival and progression of HIV disease in women attending GUM/HIV clinics in Britain and Ireland. Study Group for the MRC Collaborative Study of HIV Infection in Women. Sexually Transmitted Infections, 1999, 75, 247-252.	0.8	15
4	Does European or non-European origin influence health care and prognosis for HIV patients in Europe?. HIV Medicine, 1999, 1, 2-9.	1.0	14
5	The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. Aids, 1999, 13, 487-494.	1.0	227
6	Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. Aids, 1999, 13, 1151-1158.	1.0	61
7	Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling. Aids, 1999, 13, 1569-1576.	1.0	26
8	Changes in AIDS-Defining Illnesses in a London Clinic, 1987–1998. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 401.	0.9	52
9	Immunologic And Clinical Stages in HIV-1–Infected Ugandan Adults Are Comparable and Provide No Evidence of Rapid Progression but Poor Survival With Advanced Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 509.	0.9	34
10	Ethnic and demographic variations in HIV/AIDS presentation at two London referral centres 1995-9. Sexually Transmitted Infections, 2000, 76, 215-215.	0.8	16
11	Significance of HIV-1 Genetic Subtypes. Scandinavian Journal of Infectious Diseases, 2000, 32, 455-463.	1.5	26
13	Host Determinants in HIV Infection and Disease: Part 1: Cellular and Humoral Immune Responses*. Annals of Internal Medicine, 2001, 134, 761.	2.0	79
14	Human Immunodeficiency Virus Type 1 Clade A and D Neurotropism: Molecular Evolution, Recombination, and Coreceptor Use. Virology, 2001, 283, 19-30.	1.1	27
15	The Relationships between Ethnicity, Sex, Risk Group, and Virus Load in Human Immunodeficiency Virus Type 1 Antiretroviralâ€Naive Patients. Journal of Infectious Diseases, 2001, 183, 1518-1521.	1.9	20
16	Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. Aids, 2001, 15, 293-299.	1.0	104
17	HIV care in non-industrialised countries. British Medical Bulletin, 2001, 58, 171-186.	2.7	8
18	Rapid Disease Progression in Human Immunodeficiency Virus Type 1-Infected Seroconverters in India. AIDS Research and Human Retroviruses, 2002, 18, 1175-1179.	0.5	31
19	The sins of the fathers â€" Africans with HIV infection in London; lessons for others?. International Journal of STD and AIDS, 2002, 13, 42-44.	0.5	8

#	Article	IF	Citations
20	HIV testing and high risk sexual behaviour among London's migrant African communities: a participatory research study. Sexually Transmitted Infections, 2002, 78, 241-245.	0.8	54
21	Pathways to HIV testing and care by black African and white patients in London. Sexually Transmitted Infections, 2002, 78, 37-39.	0.8	57
22	An estimate of the contribution of HIV infection to the recent rise in tuberculosis in England and Wales. Thorax, 2002, 57, 442-445.	2.7	30
23	Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe. HIV Clinical Trials, 2002, 3, 148-154.	2.0	3
24	Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. Aids, 2002, 16, W1-W14.	1.0	107
25	HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. Aids, 2002, 16, 597-603.	1.0	309
26	Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. Aids, 2002, 16, 1139-1146.	1.0	105
27	Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 197-202.	0.9	61
28	The impact of ancillary services on primary care use and outcomes for HIV/AIDS patients with public insurance coverage. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2002, 14, 59-71.	0.6	38
29	Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study Commentary: Virus, host, or environment?. BMJ: British Medical Journal, 2002, 324, 193-197.	2.4	95
30	The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Medicine, 2002, 3, 129-134.	1.0	22
31	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. Aids, 2003, 17, 2237-2244.	1.0	76
32	HIV health experiences among migrant Africans in Europe. Aids, 2003, 17, 2261-2263.	1.0	19
33	Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. The Cochrane Library, 2003, , CD003108.	1.5	34
34	What have clinicians learnt from working with HIV/AIDS? A medical perspective from London. , 2003, , $111-147$.		5
35	Recent trends in HIV and other STIs in the United Kingdom: data to the end of 2002. Sexually Transmitted Infections, 2004, 80, 159-166.	0.8	63
36	Monitoring HIV/AIDS in Europe's migrant communities and ethnic minorities. Aids, 2004, 18, 1867-1873.	1.0	55
37	Women from Africa living with HIV in London: a descriptive study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2004, 16, 95-105.	0.6	98

#	ARTICLE	IF	CITATIONS
38	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: A Single Center Study of Epidemiologic Migration-Specific and Clinical Features. AIDS Patient Care and STDs, 2004, 18, 665-675.	1.1	30
39	Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. Aids, 2004, 18, 433-438.	1.0	41
40	Virologic and Immunologic Response to Highly Active Antiretroviral Therapy in Indigenous and Nonindigenous HIV-1???Infected Patients in The Netherlands. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 943-950.	0.9	43
41	Initial Response to Highly Active Antiretroviral Therapy in HIV-1C-Infected Adults in a Public Sector Treatment Program in Botswana. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 336-343.	0.9	108
42	High plasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland. Scandinavian Journal of Infectious Diseases, 2005, 37, 276-283.	1.5	15
43	Schistosomiasis and HIVâ€1 Infection in Rural Zimbabwe: Effect of Treatment of Schistosomiasis on CD4 Cell Count and Plasma HIVâ€1 RNA Load. Journal of Infectious Diseases, 2005, 192, 1956-1961.	1.9	120
44	Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. Aids, 2005, 19, 2141-2148.	1.0	307
45	Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study. AIDS Patient Care and STDs, 2005, 19, 599-606.	1.1	14
47	Effect of Tuberculosis Preventive Therapy on HIV Disease Progression and Survival in HIV-Infected Adults. HIV Clinical Trials, 2006, 7, 172-183.	2.0	20
48	The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and) Tj ETQq $1\ 1$	0.784314 1.0	rgBT/Over
49	Changes in AIDS-Defining Illnesses in a London Clinic, 1987???1998. Journal of Acquired Immune Deficiency Syndromes, 2006, 21, 401.	0.3	10
50	Interactions between schistosomiasis and infection with HIV-1. Parasite Immunology, 2006, 28, 060606030239010-???.	0.7	52
51	Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy. Clinical Immunology, 2006, 121, 191-197.	1.4	6
52	Access to HIV care among migrant Africans in Britain. What are the issues?. Psychology, Health and Medicine, 2006, 11, 117-125.	1.3	23
53	HIV Genetic Diversity: Biological and Public Health Consequences. Current HIV Research, 2007, 5, 23-45.	0.2	74
54	Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. Aids, 2007, 21, S55-S63.	1.0	140
55	Demographic, Clinical, and Virologic Characteristics of African-Born Persons with HIV/AIDS in a Minnesota Hospital. AIDS Patient Care and STDs, 2007, 21, 356-365.	1.1	38
56	Effect of Tuberculosis on the Survival of Women Infected with Human Immunodeficiency Virus. American Journal of Epidemiology, 2007, 165, 1134-1142.	1.6	40

#	Article	IF	CITATIONS
57	Differential improvement in survival among patients with AIDS after the introduction of HAART. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2007, 19, 523-531.	0.6	17
58	Early antiretroviral therapy mortality in resource-limited settings: what can we do about it?. Current Opinion in HIV and AIDS, 2007, 2, 346-351.	1.5	5
59	Management of advanced HIV disease with no other complications in women and in Africans. International Journal of Clinical Practice, 2007, 61, 119-129.	0.8	3
60	Health systems' responses to 25 years of HIV in Europe: Inequities persist and challenges remain. Health Policy, 2008, 86, 181-194.	1.4	15
61	Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. Aids, 2008, 22, 115-122.	1.0	148
62	Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. Aids, 2008, 22, 1869-1873.	1.0	24
63	AIDS mortality in African migrants living in Portugal: evidence of large social inequalities. Sexually Transmitted Infections, 2009, 85, 427-431.	0.8	11
64	CD4 ⁺ T Cell Count Decreases by Ethnicity among Untreated Patients with HIV Infection in South Africa and Switzerland. Journal of Infectious Diseases, 2009, 200, 1729-1735.	1.9	30
65	African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. Aids, 2009, 23, 1269-1276.	1.0	28
66	Estimation of the Predictive Role of Plasma Viral Load on CD4 Decline in HIV-1 Subtype C-Infected Subjects in India. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 119-125.	0.9	5
67	Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2010, 28, 266-272.	0.3	5
68	Viral tropism, fitness and pathogenicity of HIV-1 subtype C. Future Virology, 2010, 5, 219-231.	0.9	16
69	Human Immunodeficiency Virus Transmission. , 2011, , .		2
70	Activation and maturation of peripheral blood T cells in HIV-1-infected and HIV-1-uninfected adults in Burkina Faso: a cross-sectional study. Journal of the International AIDS Society, 2011, 14, 57.	1.2	3
71	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 111-118.	2.9	16
72	Disease Progression and Characteristics of HIV-infected Women With and Without a History of Criminal Justice Involvement. AIDS and Behavior, 2013, 17, 2644-2653.	1.4	10
73	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases, 2013, 56, 1800-1809.	2.9	28
74	Inequalities in <scp>HIV</scp> disease management and progression in migrants from <scp>L</scp> atin <scp>A</scp> merica and subâ€ <scp>S</scp> aharan <scp>A</scp> frica living in <scp>S</scp> pain. HIV Medicine, 2013, 14, 273-283.	1.0	39

#	Article	IF	CITATIONS
75	Do HIVâ€I nonâ€B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review. Journal of the International AIDS Society, 2014, 17, 18944.	1.2	35
76	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection, 2016, 22, 288.e1-288.e8.	2.8	33
77	Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. Aids, 2017, 31, 1073-1082.	1.0	18
78	Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. Aids, 2009, 23, 731-737.	1.0	38
80	HIV-1 Genetic Diversity and Its Biological Significance., 2009,, 267-291.		1
81	High Incidence of Pulmonary Tuberculosis in ART Naive Remunerated Blood Donors with Human Immunodeficiency Virus Type-1 Infection: Possible Role of Iron Overload. Journal of Biosciences and Medicines, 2018, 06, 62-82.	0.1	2
82	Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 197-202.	0.9	0
83	Low versus High CD4 Cell Count as Starting Point for Introduction of Antiretroviral Treatment in Resource-Poor Settings: A Scenario-Based Analysis. Antiviral Therapy, 2003, 8, 43-50.	0.6	7
84	Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv. Antiviral Therapy, 2004, 9, 3-12.	0.6	100